Anemia in Older Persons

MICHAEL H. BROSS, MD, University of Colorado Denver School of Medicine, Aurora, Colorado
KATHLEEN SOCH, MD, Texas A&M Health Science Center, College Station, Texas
TERESA SMITH-KNUPEL, MD, Christus Spohn Family Medicine Residency Program, Corpus Christi, Texas

Anemia in older persons is commonly overlooked despite mounting evidence that low hemoglobin levels are a significant marker of physiologic decline. Using the World Health Organization definition of anemia (hemoglobin level less than 13 g per dL [130 g per L] in men and less than 12 g per dL [120 g per L] in women), more than 10 percent of persons older than 65 years are anemic. The prevalence increases with age, approaching 50 percent in chronically ill patients living in nursing homes. There is increasing evidence that even mild anemia is associated with increased morbidity and mortality. Anemia warrants evaluation in all older persons, except those at the end of life or who decline interventions. About one third of persons have anemia secondary to a nutritional deficiency, one third have anemia caused by chronic inflammation or chronic kidney disease, and one third have unexplained anemia. Nutritional anemia is effectively treated with vitamin or iron replacement. Iron deficiency anemia often is caused by gastrointestinal bleeding and requires further investigation in most patients. Anemia of chronic inflammation or chronic kidney disease may respond to treatment of the underlying disease and selective use of erythropoiesis-stimulating agents. The treatment of unexplained anemia is difficult, and there is little evidence that treatment decreases morbidity and mortality, or improves quality of life. Occasionally, anemia may be caused by less common but potentially treatable conditions, such as autoimmune hemolytic anemia, malignancy, or myelodysplastic syndrome. (Am Fam Physician. 2010;82(5):480-487. Copyright © 2010 American Academy of Family Physicians.)
frail or who are at the end of life, discomfort from medical tests and interventions may exceed the benefits when disease burden and disability become severe. Limited overall benefits, the risk of false-positive test results, and patient preferences are valid reasons to defer evaluation. This article outlines potential causes of anemia and treatments that may be beneficial in older persons.

Etiologies
The Third National Health and Nutrition Examination Survey studied the prevalence and etiologies of anemia in a large national sample of community-dwelling persons. Most cases of anemia were mild, with only 2.8 percent of women and 1.6 percent of men having a hemoglobin level of less than 11 g per dL (110 g per L). Approximately one third of persons with anemia had a nutritional deficiency; one third had anemia of chronic inflammation, chronic kidney disease, or both; and one third had unexplained anemia. A breakdown of specific etiologies are found in Table 2.

Clinical Diagnosis
Anemia often has an insidious onset in older persons. Although an acute drop in hemoglobin will cause symptoms of volume depletion, such as dizziness and increased falls, slower onset of anemia is better tolerated, with symptoms developing as compensatory mechanisms fail. Older persons cannot increase heart rate and cardiac output as readily as younger persons, with dyspnea, fatigue, and confusion becoming more common as anemia worsens. Preexisting cardiac diseases, such as coronary artery disease and congestive heart failure, often become more symptomatic as hemoglobin levels decrease.

There are few signs on physical examination that are specific for mild or moderate anemia. Pale conjunctiva are usually noted when the hemoglobin level drops below 9 g per dL (90 g per L). In persons with multiple chronic illnesses, physicians may overlook anemia or attribute its symptoms to the underlying disease process. Thus, it is important to have a high index of suspicion.

Table 1. Risks Associated with Anemia in Older Persons

<table>
<thead>
<tr>
<th>Increased morbidity</th>
<th>Increased mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased mobility in community-dwelling older persons</td>
<td>Community-dwelling older persons</td>
</tr>
<tr>
<td>Decreased quality of life</td>
<td>Nursing home residents</td>
</tr>
<tr>
<td>Increased risk of fatigue, depression, dementia, delirium (in hospitalized patients), and falls</td>
<td>Persons with preexisting heart or kidney disease</td>
</tr>
<tr>
<td></td>
<td>Persons undergoing noncardiac surgery</td>
</tr>
</tbody>
</table>

Information from references 3 through 17.

Table 2. Etiologies of Anemia in Noninstitutionalized Persons 65 Years and Older

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Subtype</th>
<th>Percentage of anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutritional</td>
<td>Iron deficiency</td>
<td>16.6</td>
</tr>
<tr>
<td></td>
<td>Folate deficiency</td>
<td>6.4</td>
</tr>
<tr>
<td></td>
<td>Vitamin B₁₂ deficiency</td>
<td>5.9</td>
</tr>
<tr>
<td></td>
<td>Iron deficiency plus folate or vitamin B₁₂ deficiency, or all three</td>
<td>3.4</td>
</tr>
<tr>
<td></td>
<td>Folate and vitamin B₁₂ deficiencies</td>
<td>2.0</td>
</tr>
<tr>
<td>Chronic disease</td>
<td>Anemia of chronic inflammation</td>
<td>19.7</td>
</tr>
<tr>
<td></td>
<td>Renal insufficiency</td>
<td>8.2</td>
</tr>
<tr>
<td></td>
<td>Renal insufficiency and anemia of chronic inflammation</td>
<td>4.3</td>
</tr>
<tr>
<td>Unexplained</td>
<td></td>
<td>33.6</td>
</tr>
</tbody>
</table>

Anemia
d
when older persons present with even subtle symptoms of decline. A complete blood count or a point-of-care hematocrit measurement will quickly confirm the diagnosis of anemia.

Additional history and physical examination findings often clarify the etiology of anemia. Questions should address signs and symptoms associated with blood loss, such as chronic indigestion or dark stools suggestive of gastrointestinal bleeding, dark urine suggestive of hematuria, and recent surgery. Dietary history is important, with strict vegan diets increasing the risk of vitamin B12 deficiency.22 Heavy alcohol consumption increases the risk of folate deficiency22 and bleeding from peptic ulcer disease and varices. Chronic inflammatory diseases and chronic kidney disease are associated with anemia.20 A history of long-standing anemia warrants consideration of underlying malignancy and chronic infection.

Laboratory Testing and Evaluation
Once anemia is confirmed, a complete blood count is helpful. If bleeding or iron deficiency anemia is clinically suspected, measurement of serum ferritin is also warranted. The red blood cell size or mean corpuscular volume (MCV) is used to distinguish microcytic, normocytic, and macrocytic anemias. Many patients have a previously documented complete blood count that can be compared for changes in the baseline MCV. Three algorithms (Figures 123-30, 223-33, and 331-34) are presented to help identify the underlying etiology or etiologies for anemia. The algorithms are based on probabilities, with the understanding that many anemias are multifactorial, and that it is difficult to conclusively identify the underlying causes.

**MICROCYTIC ANEMIA**

Microcytic anemias (Figure 123-30) are usually caused by iron deficiency.23 Ferritin is a marker of iron storage, and a ferritin level below 35 ng per mL (78.64 pmol per L) is highly suggestive of iron deficiency anemia.23 It is important to note that ferritin levels increase with acute illness and inflammation, and in some persons with iron deficiency anemia and an acute inflammatory process, ferritin levels may be spuriously elevated. A cutoff of 45 ng per mL (101.11 pmol per L) has a higher sensitivity in older adults (Table 3).24

Iron deficiency anemia often is caused by gastrointestinal bleeding and requires further investigation in most older persons.35,36 The presence of iron deficiency anemia markedly increases the likelihood of gastrointestinal malignancy, especially in persons 65 years and older.35 Even in asymptomatic

---

**Algorithm for the diagnosis of microcytic anemia.**

Information from references 23 through 30.
Diagnosis of Normocytic Anemia

Mean corpuscular volume 80 to 100 fl

Peripheral blood smear, reticulocyte count, vitamin B₁₂ and folate levels

Abnormal peripheral blood smear?

No

Reticulocyte index* ≤ 2%?

Yes

Consider myelodysplastic syndrome, malignancy, multiple myeloma

Lactate dehydrogenase, indirect bilirubin, and haptoglobin levels; direct Coombs test

Vitamin B₁₂ and folate levels

Yes

Hemolysis

High lactate dehydrogenase level, high indirect bilirubin level, haptoglobin level ≤ 25 mg per dL (250 mg per L), or positive direct Coombs test

Normal tests

Recent blood loss, hypersplenism

Normal tests

Vitamin B₁₂ level < 100 pg per mL (73.78 pmol per L) or folate level < 5 ng per mL (11.33 nmol per L)

Vitamin B₁₂ or folate deficiency

Methylmalonic acid and homocysteine levels

Elevated methylmalonic acid level

Elevated homocysteine level

Vitamin B₁₂ deficiency

Folate deficiency

Ferritin level ≤ 45 ng per mL (101.11 pmol per L)

Iron deficiency anemia

Ferritin level 46 to 100 ng per mL (103.36 to 224.70 pmol per L)

Anemia of chronic disease with possible iron deficiency (see Figure 1)

Ferritin level > 100 ng per mL (224.70 pmol per L)

Anemia of chronic disease

Creatinine clearance ≤ 30 mL per minute per 1.73 m² (0.50 mL per second per m²)

Anemia of chronic kidney disease

*—Reticulocyte count times patient hematocrit level, divided by normal hematocrit level.

**Figure 2. Algorithm for the diagnosis of normocytic anemia.**

Information from references 23 through 33.
patients, more than one half are found to have a bleeding-related lesion on endoscopic evaluation with esophagogastroduodenoscopy and colonoscopy. Advanced age, low MCV (60 fL or less), and positive fecal occult blood test results are associated with higher rates of gastrointestinal bleeding. Despite the potential benefits of diagnosing malignancies and other pathologies, it is important to remember that the risks of perforation with colonoscopy increase with age, significant comorbidity, obstruction, and invasive interventions. Invasive diagnostic interventions are best used when they are likely to affect disease management and improve prognosis.

NORMOCYTIC ANEMIA

Normocytic anemias (Figure 23-33) have a wide differential diagnosis. Although many normocytic anemias are secondary to chronic disease, including chronic kidney disease, it is important to exclude early nutritional deficiencies and hemolysis. A peripheral blood smear, reticulocyte count, and vitamin

Table 3. Ferritin Testing in Older Persons with Anemia

<table>
<thead>
<tr>
<th>Serum ferritin level (ng per mL)</th>
<th>Likelihood ratio</th>
<th>Probability of iron deficiency anemia (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 19 (42.69 pmol per L)</td>
<td>41</td>
<td>95</td>
</tr>
<tr>
<td>19 to 45 (42.69 to 101.11 pmol per L)</td>
<td>3.1</td>
<td>61</td>
</tr>
<tr>
<td>46 to 100 (103.36 to 224.70 pmol per L)</td>
<td>0.46</td>
<td>18</td>
</tr>
<tr>
<td>&gt; 100 (224.70 pmol per L)</td>
<td>0.13</td>
<td>6</td>
</tr>
</tbody>
</table>

*—Based on an estimated 33 percent prevalence of iron deficiency anemia. Information from reference 24.
B₁₂ and folate levels should be ordered. Many patients with vitamin B₁₂ or folate deficiency have a normal MCV. If the reticulocyte index (reticulocyte count times hematocrit level, divided by normal hematocrit level) is greater than 2 percent, hemolysis and subsequent confirmatory tests should be considered. A positive direct Coombs test result strongly supports autoimmune hemolytic anemia. Autoimmune hemolytic anemia, both warm and cold antibody types, is life-threatening if untreated, but has good outcomes with immunosuppression. Other causes of reticulocytosis include recent blood loss and hypersplenism. Most persons with anemia have a low reticulocyte count, which indicates that the bone marrow is not producing adequate red blood cells. If vitamin B₁₂ and folate levels are adequate, these patients should be evaluated for iron deficiency anemia and kidney disease. Many older persons have a mixed anemia with more than one etiology. The soluble transferrin receptor level is typically increased to 2.5 mg per L (29.5 nmol per L) greater with iron deficiency anemia. When dividing the soluble transferrin receptor level by the log of the ferritin level, a value of 1.5 or less suggests anemia of chronic disease and a value greater than 1.5 supports iron deficiency with chronic disease.

**MACROCYTIC ANEMIA**

Macrocytic anemias (Figure 3) may be caused by drug therapy, alcoholism, liver disease, hypothyroidism, vitamin B₁₂ deficiency, or folate deficiency. An elevated reticulocyte count suggests hemolysis, hypersplenism, or recent blood loss. When the reticulocyte count is low, the next step is to obtain serum vitamin B₁₂ and folate levels. If the vitamin B₁₂ or folate level is borderline low, serum homocysteine level (to confirm folate deficiency) and methylmalonic acid level (to confirm vitamin B₁₂ deficiency) should be obtained. Normal levels of homocysteine and methylmalonic acid virtually exclude folate and vitamin B₁₂ deficiencies.

An abnormal peripheral blood smear result in patients with anemia warrants strong consideration for myelodysplastic syndrome and malignancies, especially multiple myeloma. Macrocytic anemia is associated with myelodysplastic syndrome and myeloproliferative conditions. In such cases, bone marrow biopsy should be considered if the findings would potentially affect treatment.

**Treatment**

Almost all older persons with nutritional anemia should be treated, because treatment is usually simple and cost-effective. The only exceptions may be very ill patients at the end of life and those who decline interventions. For iron deficiency anemia, the usual replacement dose is ferrous sulfate, 325 mg (65 mg of elemental iron) per day, or ferrous gluconate, 325 mg (38 mg of elemental iron) per day. Low-dose iron therapy, with 15 mg of elemental iron per day as liquid ferrous gluconate, effectively corrects hemoglobin and ferritin concentrations with fewer gastrointestinal adverse effects than higher iron doses. Treatment is usually continued for six months to replete iron stores. For persons who fail to respond to oral iron therapy, parenteral treatment with iron dextran or iron sucrose is usually therapeutic. High-dose oral therapy (cyanocobalamin, 1 to 2 mg per day) to treat vitamin B₁₂ deficiency is effective and well tolerated. Folate deficiency should be treated with folic acid, 1 mg per day. Effective treatment of nutritional anemia is noted by reticulocytosis within one week, followed by a more gradual increase in hemoglobin level.

Treatment of anemia of chronic disease, chronic kidney disease anemia, and unexplained anemia is more difficult. The initial and preferred treatment is to correct the underlying disorder. Optimal management of chronic diseases will minimize inflammation and lessen bone marrow suppression. Most anemias in older persons are mild and do not require further intervention. When anemia is severe (hemoglobin level less than 10 g per dL [100 g per L]), symptoms that warrant additional treatment often develop. Two options to treat severe anemia are blood transfusions and erythropoiesis-stimulating agents, both of which have significant limitations. Blood transfusions provide immediate relief of common symptoms, including dyspnea, fatigue, and dizziness. Risks of transfusions include volume overload, iron overload, infections, and acute reactions.

Erythropoiesis-stimulating agents have been approved for the treatment of anemia of chronic disease in limited situations (Table 4), but their use remains controversial. Erythropoetin is produced mainly by the kidneys and stimulates the production of red blood cells in the bone marrow. Two recent randomized trials of the use of erythropoiesis-stimulating agents in persons with chronic kidney disease and anemia found that increasing the hemoglobin level to a target of 13.5 g per dL (135 g per L) or 13 g per dL resulted in an increased rate of death and cardiovascular events. Goals of treatment with erythropoiesis-stimulating agents for chronic kidney disease are avoiding transfusions and maintaining a hemoglobin level significantly below 12 g per dL. Although some studies have shown modest benefits of erythropoiesis-stimulating agents in persons with cancer and anemia, several have found decreased survival with these agents. For selected chemotherapy-
Anemia

Table 4. Guidelines for Use of Erythropoiesis-Stimulating Agents in Patients with Anemia

<table>
<thead>
<tr>
<th>Indications approved by the U.S. Food and Drug Administration</th>
<th>Other indications covered by Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persons with anemia of chronic kidney disease undergoing dialysis to maintain a hemoglobin level of 10 to 12 g per dL (100 to 120 g per L)</td>
<td>Current indications need to be reevaluated</td>
</tr>
<tr>
<td>Persons with a hemoglobin level less than 10 g per dL who currently are on chemotherapy for cancer</td>
<td>Certain persons with myelodysplastic syndrome</td>
</tr>
<tr>
<td>Persons with human immunodeficiency virus infection and anemia secondary to zidovudine (Retrovir) therapy</td>
<td>Persons undergoing treatment for hepatitis C</td>
</tr>
<tr>
<td>Persons with anemia scheduled for surgery who are at risk of needing surgery-associated blood transfusion (epoetin alfa [EpoGen] only)</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td>Systemic lupus erythematosus</td>
</tr>
</tbody>
</table>

Information from references 44 through 47.

For most persons with anemia of chronic disease or unexplained anemia, there is little evidence that correcting the hemoglobin level decreases morbidity and mortality, or improves quality of life. In these patients, anemia may be a marker of frailty and physiologic decline. Therefore, it is prudent to limit erythropoiesis-stimulating agents to the treatment of severe anemia associated with chronic kidney disease and other approved indications, unless patients are part of clinical trials to evaluate erythropoiesis-stimulating agents.

Newer treatment modalities for myelodysplastic syndrome and multiple myeloma may prove beneficial regardless of patient age. Hematology consultation should be obtained if treatment is desired.

The authors thank Sally P. Stabler, MD, professor of medicine and co-head of the Division of Hematology at the University of Colorado Denver, for her review of the manuscript.

The Authors

MICHAEL H. BROSS, MD, is an associate professor in the Department of Family Medicine at the University of Colorado Denver School of Medicine in Aurora.

KATHLEEN SOCH, MD, is an associate professor of family medicine at the Texas A&M Health Science Center in College Station, and the director of geriatric training in the Christus Spohn Family Medicine Residency Program, Corpus Christi, Tex.

TERESA SMITH-KNUPPEL, MD, is a geriatric fellow in the Christus Spohn Family Medicine Residency Program.

Address correspondence to Michael H. Bross, MD, University of Colorado Denver School of Medicine, 3055 Roslyn St., Ste. 100, Denver, CO 80238 (e-mail: michael.bross@ucdenver.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

16. McClellan WM, Flanders WD, Langston RD, Jurkovicz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among


